Westpac Banking Corp Takes $8.39 Million Position in Stryker Corporation $SYK

Key Points

• Westpac Banking Corp purchased 26,663 Stryker shares worth approximately $8.39 million in the second quarter, adding to broad institutional interest; institutions now own about 77.1% of the company.
• Stryker’s latest quarter exceeded expectations, with earnings of $3.69 per share and revenue of $6.59 billion, up 9.4% year over year. The company maintained fiscal 2026 earnings guidance of $14.95–$15.10 per share and declared a quarterly dividend of $0.88.
• Analysts remain broadly positive, assigning the stock a “Moderate Buy” consensus and an average price target of $386.28, but recent target cuts and substantial insider selling—including Director Ronda Stryker’s share sales—highlight near-term caution.

Westpac Banking Corp purchased a new position in shares of Stryker Corporation (NYSE:SYK - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 26,663 shares of the medical technology company's stock, valued at approximately $8,395,000.

Several other institutional investors have also bought and sold shares of SYK. Norges Bank purchased a new stake in Stryker in the fourth quarter worth $1,822,272,000. Auto Owners Insurance Co lifted its position in shares of Stryker by 35,047.0% during the 4th quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company's stock valued at $1,024,444,000 after buying an additional 2,906,448 shares during the last quarter. Flossbach Von Storch SE purchased a new position in shares of Stryker during the 2nd quarter valued at $464,506,000. Wellington Management Group LLP grew its stake in shares of Stryker by 22.6% during the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company's stock worth $2,282,192,000 after acquiring an additional 1,198,665 shares during the period. Finally, Corient Private Wealth LLC increased its holdings in Stryker by 104.4% in the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company's stock worth $887,525,000 after acquiring an additional 1,146,998 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company's stock.

Stryker News Summary

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here's Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Wall Street Analyst Weigh In

Several equities research analysts have commented on SYK shares. Sanford C. Bernstein set a $410.00 price objective on shares of Stryker in a report on Friday, May 1st. Needham & Company LLC reduced their target price on shares of Stryker from $454.00 to $418.00 and set a "buy" rating for the company in a research note on Friday, May 1st. Leerink Partners lowered their price target on shares of Stryker from $410.00 to $407.00 and set an "outperform" rating on the stock in a research report on Friday, June 5th. Raymond James Financial set a $370.00 price target on shares of Stryker in a research note on Friday, July 31st. Finally, Wall Street Zen raised shares of Stryker from a "hold" rating to a "buy" rating in a report on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company. According to MarketBeat, Stryker currently has a consensus rating of "Moderate Buy" and an average price target of $386.28.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 50,000 shares of the business's stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the completion of the transaction, the director owned 2,251,375 shares of the company's stock, valued at approximately $765,692,637.50. The trade was a 2.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of the company's stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 665,370 shares of company stock valued at $216,238,501 in the last 90 days. Corporate insiders own 4.60% of the company's stock.

Stryker Stock Up 0.7%

SYK opened at $329.86 on Friday. The company has a fifty day moving average price of $326.99 and a 200-day moving average price of $332.64. The firm has a market capitalization of $126.52 billion, a P/E ratio of 34.18, a price-to-earnings-growth ratio of 2.09 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. Stryker Corporation has a one year low of $281.00 and a one year high of $396.86.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion for the quarter, compared to analysts' expectations of $6.58 billion. During the same quarter in the prior year, the firm posted $3.13 earnings per share. The business's quarterly revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts expect that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker's dividend payout ratio is currently 36.48%.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source